Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Zendy

Philip J. Mease | Zendy; Iain B. McInnes | Zendy; Bruce Kirkham | Zendy; Arthur Kavanaugh | Zendy; Proton Rahman | Zendy; Désirée van der Heijde | Zendy; R. Landewé | Zendy; Peter Nash | Zendy; Luminita Pricop | Zendy; Jiacheng Yuan | Zendy; Hanno B. Richards | Zendy; Shephard Mpofu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Author(s) -

Philip J. Mease,

Iain B. McInnes,

Bruce Kirkham,

Arthur Kavanaugh,

Proton Rahman,

Désirée van der Heijde,

R. Landewé,

Peter Nash,

Luminita Pricop,

Jiacheng Yuan,

Hanno B. Richards,

Shephard Mpofu

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1412679

Subject(s) - secukinumab , medicine , psoriatic arthritis , placebo , clinical endpoint , rheumatology , arthritis , subcutaneous injection , gastroenterology , clinical trial , dermatology , pathology , alternative medicine

In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research